L01XX02 - Asparaginase |
Not porphyrinogenic |
NP |
Rationale
Enzyme. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Chemical description
Asparaginase is an enzyme derived from Escherichia coli, that converts L-aspargine to aspartic acid and ammonia.
Therapeutic characteristics
Asparaginase is an antineoplastic agent used for induction of remission in acute lymphattic leucemia. It is administered as an intravenous administration. Common adverse reactions of asparaginase that can be confused with an acute porphyric attack are nausea, vomiting, depression, confusion and irritability. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Hepatic exposure
Not relevant.
Published experience
Uneventful use reported in one 16-year old female patient with PV (Samuels, 1984).
References
- Scientific articles
- Samuels B, Bezwoda WR, et al. Chemotherapy in porphyria. S Afr Med J 1984; 65(23):924-6. PMID 6587589. #4581
- Drug reference publications
- McEvoy GK, editor. Asparaginase. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (07.06.10). #2082
- Sweetman SC, editor. Martindale: The complete drug reference. Asparaginase. Pharmaceutical Press 2009. #2084
Similar drugs
© NAPOS 2024